Phylogica has established relationships with multinational pharmaceutical and biotechnology companies and world-class research institutes including;
Johnson & Johnson Research Pty Ltd
Phylogica signed an agreement with Johnson and Johnson Research Pty Ltd (JJR), an entrepreneurial subsidiary of the Johnson & Johnson (J&J) group of global healthcare companies. Under the terms of agreement, the companies will collaborate to develop novel compounds using Phylomer® technology, and if successful the relevant Phylomer® compounds will then be licensed to and developed exclusively by JJR. Phylogica will receive both upfront fees and milestone payments under the terms of agreement.
Opsona Therapeutics
Phylogica is also collaborating with companies that have novel disease targets to develop new Phylomer® drugs and share the revenues. The deal signed with Opsona Therapeutics of Ireland is to discover and develop new anti-inflammatory drugs. Opsona Therapeutics is a drug discovery and development company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases.
Following successful completion of the agreement, the intention of both parties is for the relevant Phylomer® compounds to be out-licensed and developed by Opsona, with Phylogica to share in the revenue stream.
Phylogica has also established collaborations with biotechnology companies, and research institutes based on synergies in technology, drug development expertise and science.
Australian Neuromuscular Research Institute
Phylogica is collaborating with the Cerebrovascular Diseases Research Group at the Australian Neuromuscular Research Institute to access experimental stroke models to test its Phylomer® stroke peptides. This collaboration was partly funded under the AusIndustry, AU $250,000 Biotechnology Innovation Fund Program. The intellectual property surrounding the Phylomer® peptides is wholly owned by Phylogica.
Baker Heart Research Institute
Phylogica is collaborating with the Baker Heart Research Institute (Baker) to develop Phylomer® drugs that could improve heart surgery outcomes for patients. Under the terms of the collaboration, Baker will assess Phylomer® candidates for their ability to prevent cell death in model systems developed by Baker. If the collaboration is successful, then the Phylomer® compounds will progress to pre-clinical trials.
Fox Chase Cancer Center and Massachusetts General Hospital
Fox Chase Cancer Center (Fox Chase), a world leader in cancer research based in Philadelphia (USA) and Massachusetts General Hospital, granted Phylogica an exclusive global license for novel technology that broadens Phylogica’s technology application and has the potential to generate revenue stream from sub-licensing of the technology. Phylogica is collaborating directly with Fox Chase in applying the technology to screen against a validated target in both cancer and inflammatory diseases.
McComb Foundation
Researchers at the McComb Foundation (McComb) have applied Phylomer® drugs topically to burns injuries and the initial results have been promising. On the strength of the results, Phylogica has now concluded a commercialisation agreement with McComb. The deal gives Phylogica exclusive commercialisation rights for its Phylomer® drugs for the treatment of wound healing and scar tissue formation, in return for a revenue sharing arrangement with McComb.
Mimotopes
Phylogica and PharmAust’s Melbourne-based subsidiary Mimotopes signed a partnering deal to use complementary technology platforms to develop next generation peptide drugs. Mimotopes’ Synphase platform, incorporates complementary technology that will enable the rapid production and optimisation of large libraries of the Phylomer® peptides identified by Phylogica as potential therapeutics.
Murdoch University
Phylogica has completed an agreement with Murdoch University (Murdoch) to collaborate on the rheumatoid arthritis (RA) project. Phylogica is collaborating with Murdoch to test its Phylomer® peptides in cell culture models of RA. This project is partly funded under the AusIndustry, AU $2.27 million Commercial Ready Program grant.
Swiss Institute of Allergy & Asthma Research
Phylogica is collaborating with the prestigious Swiss Institute of Allergy & Asthma Research (SIAF). The collaboration involves the screening of Phylogica’s proprietary Phylomer® libraries for potential vaccine leads for the treatment of allergies and asthma. If successful, the program will generate novel vaccine antigens that can be developed for allergen immunotherapy – the desensitisation of allergic individuals to common antigens like bee venom and birch pollen. Moreover, this technology has applicability for the common house dust mite, pollen and grass allergies.
University of Melbourne
Phylogica has completed an agreement with the University of Melbourne (University) to collaborate on the rheumatoid arthritis (RA) project. The University has an international reputation in the field of RA and associated inflammatory diseases. Phylogica is collaborating with the University to assay its Phylomer® peptides in RA models established at the University. This collaboration is partly funded under the AusIndustry, AU $2.27 million Commercial Ready Program grant.
University of Tasmania
Phylogica has an agreement with The University of Tasmania (UTAS) (www.utas.edu.au), through its commercial arm UTAS Innovation Ltd, to test its Phylomer® stroke peptides in UTAS’s established head injury models.
University of Western Australia
The University of Western Australia (UWA) has signed two research collaborations with Phylogica to access the company’s Phylomer® technology. UWA is screening Phylogica’s library to identify Phylomer® peptides that discriminate between proteins that are phosphorylated or unphosphorylated, one of the key mechanisms by which proteins control the physiology of a cell. The projects are focused on proteins implicated in cancer and stroke. The objective of these projects is to achieve a greater understanding of the mechanism of control of proteins in diseases, which is key in developing treatments to these diseases. In both cases, Phylogica and UWA will jointly own all intellectual property emanating from the projects.
